Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 7.30
HPTX's Cash to Debt is ranked higher than
67% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. HPTX: 7.30 )
HPTX' s 10-Year Cash to Debt Range
Min: 0.12   Max: No Debt
Current: 7.3

Equity to Asset 0.70
HPTX's Equity to Asset is ranked higher than
75% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. HPTX: 0.70 )
HPTX' s 10-Year Equity to Asset Range
Min: 0.5   Max: 0.87
Current: 0.7

0.5
0.87
F-Score: 5
Z-Score: 5.65
M-Score: -1.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -10.61
HPTX's Operating margin (%) is ranked higher than
81% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. HPTX: -10.61 )
HPTX' s 10-Year Operating margin (%) Range
Min: -31.79   Max: -31.79
Current: -10.61

Net-margin (%) -13.40
HPTX's Net-margin (%) is ranked higher than
80% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. HPTX: -13.40 )
HPTX' s 10-Year Net-margin (%) Range
Min: 39.4   Max: 39.4
Current: -13.4

ROE (%) -10.72
HPTX's ROE (%) is ranked higher than
81% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. HPTX: -10.72 )
HPTX' s 10-Year ROE (%) Range
Min: 21.58   Max: 21.58
Current: -10.72

ROA (%) -7.55
HPTX's ROA (%) is ranked higher than
82% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. HPTX: -7.55 )
HPTX' s 10-Year ROA (%) Range
Min: -722.57   Max: 17.17
Current: -7.55

-722.57
17.17
ROC (Joel Greenblatt) (%) -747.22
HPTX's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. HPTX: -747.22 )
HPTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -275357.89   Max: -2724.26
Current: -747.22

-275357.89
-2724.26
» HPTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

HPTX Guru Trades in Q2 2013

Louis Moore Bacon Sold Out
Steven Cohen Sold Out
RS Investment Management 73,078 sh (-2.43%)
» More
Q3 2013

HPTX Guru Trades in Q3 2013

RS Investment Management Sold Out
» More
Q2 2014

HPTX Guru Trades in Q2 2014

Jim Simons 34,400 sh (New)
» More
Q3 2014

HPTX Guru Trades in Q3 2014

Joel Greenblatt 18,109 sh (New)
Jim Simons 118,000 sh (+243.02%)
» More
» Details

Insider Trades

Latest Guru Trades with HPTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 New Buy$21.96 - $27.64 $ 22.97-8%18109
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.84
HPTX's P/B is ranked higher than
81% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. HPTX: 3.84 )
HPTX' s 10-Year P/B Range
Min: 3.09   Max: 5.76
Current: 3.84

3.09
5.76
P/S 4.68
HPTX's P/S is ranked higher than
90% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. HPTX: 4.68 )
HPTX' s 10-Year P/S Range
Min: 4.3   Max: 516.4
Current: 4.68

4.3
516.4
PFCF 14.70
HPTX's PFCF is ranked higher than
98% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. HPTX: 14.70 )
HPTX' s 10-Year PFCF Range
Min: 13.22   Max: 40.65
Current: 14.7

13.22
40.65
EV-to-EBIT -33.33
HPTX's EV-to-EBIT is ranked higher than
60% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. HPTX: -33.33 )
HPTX' s 10-Year EV-to-EBIT Range
Min: -194.9   Max: 25.7
Current: -33.33

-194.9
25.7
Current Ratio 4.69
HPTX's Current Ratio is ranked higher than
73% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. HPTX: 4.69 )
HPTX' s 10-Year Current Ratio Range
Min: 0.11   Max: 11.32
Current: 4.69

0.11
11.32
Quick Ratio 4.57
HPTX's Quick Ratio is ranked higher than
73% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. HPTX: 4.57 )
HPTX' s 10-Year Quick Ratio Range
Min: 0.11   Max: 11.27
Current: 4.57

0.11
11.27

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.83
HPTX's Price/Net Cash is ranked higher than
88% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. HPTX: 5.83 )
HPTX' s 10-Year Price/Net Cash Range
Min: 4.32   Max: 6.61
Current: 5.83

4.32
6.61
Price/Net Current Asset Value 4.94
HPTX's Price/Net Current Asset Value is ranked higher than
89% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. HPTX: 4.94 )
HPTX' s 10-Year Price/Net Current Asset Value Range
Min: 4.32   Max: 5.89
Current: 4.94

4.32
5.89
Price/Tangible Book 4.19
HPTX's Price/Tangible Book is ranked higher than
84% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. HPTX: 4.19 )
HPTX' s 10-Year Price/Tangible Book Range
Min: 3.83   Max: 5.76
Current: 4.19

3.83
5.76
Price/Median PS Value 0.40
HPTX's Price/Median PS Value is ranked higher than
96% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. HPTX: 0.40 )
HPTX' s 10-Year Price/Median PS Value Range
Min: 0.45   Max: 43.03
Current: 0.4

0.45
43.03
Earnings Yield (Greenblatt) -3.00
HPTX's Earnings Yield (Greenblatt) is ranked higher than
79% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. HPTX: -3.00 )
HPTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.9   Max: 5
Current: -3

3.9
5

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0HY.Germany,
Hyperion Therapeutics Inc., was incorporated in Delaware on November 1, 2006. The Company completed its initial public offering on July 2012. It is a commercial biopharmaceutical company, engaged in the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Its products, RAVICTI (glycerol phenylbutyrate) Oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) Tablets and Powder, are designed to lower ammonia in the blood. The Company has developed RAVICTI to treat urea cycle disorders including 7 of the 8 prevalent UCD subtypes, and is developing glycerol phenylbutyrate, the active pharmaceutical ingredient in RAVICTI, to treat hepatic encephalopathy. RAVICTI is indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients above 2 years of age with urea cycle disorders who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. It distributes RAVICTI through two specialty pharmacies with a single dedicated call center responsible for interfacing with patients, physicians and payors. BUPHENYL is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. The Company faces competition from established pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions, among others, which may in the future develop products to treat UCD or HE. The Company is subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.
» More Articles for HPTX

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Hyperion Therapeutics Added to Nasdaq Biotechnology Index (NBI) Dec 18 2014
Hyperion Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference Dec 04 2014
HYPERION THERAPEUTICS INC Financials Nov 14 2014
Hyperion Therapeutics (HPTX) Downgraded From Hold to Sell Nov 14 2014
Hyperion Therapeutics to Present at the Jefferies 2014 Global London Healthcare Conference Nov 13 2014
Hyperion Therapeutics to Present at the Jefferies 2014 Global London Healthcare Conference Nov 13 2014
Hyperion tops 3Q revenue forecasts Nov 06 2014
Hyperion tops 3Q revenue forecasts Nov 06 2014
Hyperion Therapeutics Inc Earnings Call scheduled for 4:05 pm ET today Nov 06 2014
Hyperion Therapeutics Announces Third Quarter 2014 Financial Results Nov 06 2014
HYPERION THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change... Nov 06 2014
Hyperion Therapeutics Announces Third Quarter 2014 Financial Results Nov 06 2014
Q3 2014 Hyperion Therapeutics Inc Earnings Release - After Market Close Nov 06 2014
Street Talk: Downgrade for Deans Nov 03 2014
Coverage initiated on Hyperion Therapeutics by ROTH Capital Nov 03 2014
Hyperion Therapeutics to Report Third Quarter 2014 Financial Results After Market on November 6,... Oct 31 2014
Hyperion Therapeutics to Report Third Quarter 2014 Financial Results After Market on November 6,... Oct 31 2014
Avanir (AVNR) Presents Detailed Phase II Data on AVP-923 Oct 14 2014
Hyperion, Clal Biotech resolve dispute over diabetes drug Oct 07 2014
Hyperion Therapeutics and Clal Biotechnology Industries Ltd. Enter Into Interim Agreement Oct 07 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK